PERCEPTIVE INFORMATICS EXPANDS MEDICAL IMAGING CORE LAB SERVICES IN EUROPE
BOSTON, MA, October 24, 2003 — Perceptive Informatics, Inc. (Perceptive), a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced the expansion of its medical imaging core lab services in Europe. Imaging can be used as a surrogate endpoint in clinical trials, supporting earlier “go/no go” portfolio management decisions and judgments relating to efficacy and safety.
Perceptive Informatics will offer expanded centralized imaging services from its Berlin, Germany location. Centralized imaging services are valuable in minimizing variability in image acquisition techniques and analysis results so that the power of the clinical trial is not compromised. Perceptive has experience with a broad array of imaging modalities including computed tomography (CT), magnetic resonance (MR) imaging, positron emission tomography (PET), ultrasound, nuclear medicine, and conventional radiography among others. The company’s capabilities range from the application of novel imaging techniques in early drug development to widely validated methods for registration trials.
Perceptive’s global infrastructure enables image collection from investigator sites around the world for multi-center clinical trials. Additionally, a 24-hour, 7-day-a-week call center with multi-lingual support in 140 languages provides site support and proactive training.
“Perceptive focuses on providing technology-based products and services that improve the development processes of our clients,” said Mark A. Goldberg, MD, President of Perceptive Informatics, Inc. “While we have been supporting global imaging trials for many years, our expansion provides European clients with closer proximity to our innovative imaging solutions. With appropriate planning and execution, medical imaging can be successfully implemented as a trial endpoint with the potential for significant savings in development time.”
Additions to the Berlin office include staff members Oliver Bohnsack, MD, MBA, a board-certified diagnostic radiologist, and Thomas Berger, MD, PhD.
Dr. Bohnsack brings to Perceptive over fourteen years of diverse medical and healthcare management experience. Prior to joining Perceptive, Dr. Bohnsack served as healthcare consultant at Covidence, a contract research organization. He received his medical degree from the University of Essen, Germany, and a Masters of Business Administration from the University of California, Irvine.
Dr. Berger joins Perceptive as a physician and research scientist in the emerging fields of telemedicine and e-health. Dr. Berger earned his medical degree from Heinrich-Heine-University Düsseldorf Medical School, Germany. He earned a degree in Medical Informatics from Lower Rhine Area Medical Association, Germany, and a PhD in Medical Informatics from the German Society for Informatics and German Society for Medical Informatics, Biometry and Epidemiology, Köln, Germany.
Perceptive Informatics, Inc. develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), and clinical trial management systems (CTMS). IMPACT is Perceptive's market leading CTMS product and INITIATOR is a trial management product targeted to the needs of Phase I units. Perceptive offers advanced medical imaging services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. In addition, the company provides electronic diary and investigator database solutions. Perceptive is headquartered near Boston, MA with approximately 270 employees in offices located throughout North America and Europe. Perceptive Informatics is a subsidiary of PAREXEL International Corporation.
PAREXEL is a registered trademark of PAREXEL International Corporation. Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding the Company’s existing capital resources and future cash flows from operations, and statements regarding expected financial results, future growth and customer demand, such as the guidance provided by the Company with respect to the second quarter of Fiscal Year 2004 and the full Fiscal Year 2004. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2003 as filed with the Securities and Exchange Commission on September 15, 2003, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.